Bringing the very best science and medicine to our best equine friends
November 2015

Kindred Biosciences Announces Positive Results from Pivotal Study of KIND-012 for Pyrexia in Horses, and Provides Other Product Updates

KIND-012 study meets primary endpoint with p<0.0001. Data to be filed with the FDA for approval. SentiKind study misses primary endpoint. Conference call and webcast scheduled for 5:00 p.m. Eastern Time today. San Francisco, CA (November 16, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pivotal field study (KB0120) of KIND-012 for the control of pyrexia (fever) in horses.

Continue Reading

Kindred Biosciences Announces Third Quarter 2015 Financial Results

San Francisco, CA (November 9, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the third quarter ended September 30, 2015 and provided updates on its programs. Development and Corporate Updates KindredBio continues to advance a diversified portfolio of molecules in a capital efficient manner. Some of the recent highlights include: SentiKind™, or KIND-090, pivotal study. The pivotal field study of SentiKind, a KCNQ potassium channel agonist for post-operative pain in dogs, completed enrollment and the Company plans to report topline results in the coming weeks. The Chemical, Manufacturing, and Controls (CMC) and Target Animal Safety Study (TASS) …

Continue Reading